Back to Search
Start Over
Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group
- Source :
- Journal of Clinical Oncology. 27:2686-2691
- Publication Year :
- 2009
- Publisher :
- American Society of Clinical Oncology (ASCO), 2009.
-
Abstract
- Purpose To estimate the antitumor activity of pemetrexed in patients with persistent or recurrent platinum-resistant epithelial ovarian or primary peritoneal cancer and to determine the nature and degree of toxicities. Patients and Methods A phase II trial was conducted by the Gynecologic Oncology Group. Patients must have had cancer that had progressed on platinum-based primary chemotherapy or recurred within 6 months. Pemetrexed at a dose of 900 mg/m2 was to be administered as an intravenous infusion over 10 minutes every 21 days. Dose delay and adjustment was permitted for toxicity. Treatment was continued until disease progression or unacceptable adverse effects. Results From July 6, 2004, to August 23, 2006, 51 patients were entered. A total of 259 cycles (median, four; range one to 19 cycles) of pemetrexed were administered, with 40% of patients receiving six or more cycles. Overall, the treatment was well tolerated. More serious toxicities (grade 3 and 4) included neutropenia in 42%, leukopenia in 25%, anemia in 15%, and constitutional in 15% of patients. No treatment-related deaths were reported. One patient (2%) had a complete and nine patients (19%) had partial responses, with a median duration response of 8.4 months. Seventeen patients (35%) had stable disease for a median of 4.1 months. Eighteen patients (38%) had increasing disease. Three patients (6%) were not assessable. Median progression-free survival was 2.9 months, and overall survival was 11.4 months. Conclusion Pemetrexed has sufficient activity in the treatment of recurrent platinum-resistant ovarian cancer at the dose and schedule tested to warrant further investigation.
- Subjects :
- Adult
Cancer Research
medicine.medical_specialty
Guanine
Time Factors
Antineoplastic Agents
Platinum Compounds
Pemetrexed
Gynecologic oncology
Neutropenia
Gastroenterology
Disease-Free Survival
Drug Administration Schedule
Primary peritoneal carcinoma
Glutamates
Recurrence
Internal medicine
Original Reports
medicine
Carcinoma
Humans
Treatment Failure
Infusions, Intravenous
Adverse effect
Peritoneal Neoplasms
Aged
Aged, 80 and over
Ovarian Neoplasms
Leukopenia
business.industry
Middle Aged
medicine.disease
United States
Surgery
Oncology
Drug Resistance, Neoplasm
Folic Acid Antagonists
Female
medicine.symptom
Ovarian cancer
business
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 27
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi.dedup.....2e54f1bdf62a53166a5c2177feb8a9d5